Stopping immunotherapy after bladder cancer disappears
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether it's safe to stop immunotherapy once bladder cancer is no longer visible, instead of continuing it for a longer time. It aims to find out if stopping treatment early can reduce side effects while keeping the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a high-risk bladder cancer that has not spread into the bladder muscle.
- Your tumor could not be fully removed with surgery (TURBT) because it was too large or widespread.
- You have already received immunotherapy (PD-1/PD-L1 inhibitor) as part of your treatment.
- Your cancer is currently not visible on any tests (cystoscopy, biopsy, urine tests, or imaging).
- You are in good general health (able to do daily activities) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (toripalimab) and a chemotherapy drug (gemcitabine) given directly into the bladder after surgery to remove high-risk bladder tumors. The goal is to reduce the chance of the cancer coming back.
This study tests a combination of a targeted drug (disitamab vedotin), an immunotherapy drug (PD-1 inhibitor), and radiation therapy as a way to treat bladder cancer without removing the bladder. It is for people whose cancer has grown into the bladder muscle but hasn't spread to other parts of the body, and whose tumor shows high HER2 levels.
This study tests an immunotherapy drug (toripalimab) alone or followed by medication placed directly into the bladder (gemcitabine and mitomycin C) for people with high-risk bladder cancer that has not spread into the muscle wall and that has not responded to or couldn't be handled with BCG therapy. The goal is to see which approach works better.
This study watches people with muscle-invasive bladder cancer who choose to keep their bladder after receiving neoadjuvant therapy (treatment before the main treatment). It aims to see how well bladder-preserving treatments like chemoradiation work over time.
This trial studies pembrolizumab (an immunotherapy) in people with muscle-invasive bladder cancer who had a combined “trimodality” treatment and then achieved a complete response. The goal is to help control the cancer after the initial treatment is finished.
This trial tests a new immunotherapy approach for people with a very high risk type of bladder cancer that hasn't spread into the muscle layer. The treatment is guided by a special urine test that looks for tumor DNA, and it may help if surgery cannot remove all the cancer or you choose not to have your bladder removed.
Hear when a new Bladder (Urothelial, Transitional Cell) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.